title: Guillain-Barré syndrome as leading manifestation of graft-versus-host disease in an allogeneic bone marrow transplanted patient.
abstract: Guillain-Barré Syndrome (GBS) is the most frequent cause of neuromuscular paralysis in industrialized countries and usually occurs after respiratory and gastrointestinal infections. However, in rare cases GBS is associated with Graft-versus-Host Disease (GvHD). In the present case we report on a female allogeneic bone marrow transplanted patient who developed GBS as a leading manifestation of GvHD subsequent to discontinuation of her immunosuppressive medication with cyclosporine. In contrast to former case reports both IVIg and plasma exchange failed while resumption of immunosuppressive medication improved the condition of the patient clearly.
authors.affiliation: Department of Neurology, Clinical Center Nuernberg South, Breslauerstr. 201, 90471 Nuernberg, Germany. Jan_Thoene@gmx.de
authors.forename: Jan
authors.initials: J
authors.lastname: Thöne
authors.forename: Susanne
authors.initials: S
authors.lastname: Lamprecht
authors.forename: Andreas
authors.initials: A
authors.lastname: Hohaus
authors.forename: Frank
authors.initials: F
authors.lastname: Erbguth
authors.forename: Andreas
authors.initials: A
authors.lastname: Bickel
mesh_terms: D016026:Bone Marrow Transplantation; D005260:Female; D006086:Graft vs Host Disease / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D020275:Guillain-Barre Syndrome / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008875:Middle Aged; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents